跳至主要内容
临床试验/ACTRN12615000439549
ACTRN12615000439549已完成1 期

A Phase 1 Randomised, Double Blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Intra-articular Progenza (PRG) in Adults with Symptomatic Knee Osteoarthritis

Regeneus Ltd0 个研究点目标入组 20 人开始时间: 2015年5月7日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
Regeneus Ltd
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
40 Years 至 65 Years(—)
性别
All

入选标准

  • Patients will be eligible to participate if they:
  • - are between 40 and 65 years of age inclusive
  • - have Kellgren-Lawrence grade 1, 2 or 3 symptomatic knee osteoarthritis.
  • - have moderate to severe knee pain associated with OA

排除标准

  • Patients will not be eligible to participate if they:
  • - have OA in the non-study knee that has worse pain than the study knee
  • - have had joint surgery in the past 3 years
  • - have major mechanical issues in the study knee
  • - have significant OA in other major joints

研究者

发起方
Regeneus Ltd

相似试验

已完成
1 期
A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KZR-616 in Healthy Subjects
ACTRN12616001040459Clinical Network Services128
尚未招募
1 期
A study to evaluate the Safety and Pharmacokinetics (Pharmacokintecus, the measure of how the human body processes a substance) of ETX0282 when administered orally to healthy participants.
ACTRN12618000350224INC Research/ Inventiv Health116
已完成
不适用
A Phase 1, Randomized, Double-blind, Placebo controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX*150 in Healthy Male AdultsPain10029305
NL-OMON46528Vertex Pharmaceuticals20
尚未招募
1 期
A Phase 1, Randomised, Double-Blind, placebo controlled, single and multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of KZR-616 in healthy female subjects.Chronic inflammatory conditions for example rheumatoid arthritisAutoimmune disorders for example systemic lupus erythematosusInflammatory and Immune System - Autoimmune diseases
ACTRN12618002060224Clinical Netwprk Services72
已完成
不适用
A Phase 1 Randomized, Double-blind, Placebo-controlled, Single-dose and Multiple-dose Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-1821 in Healthy Adult Volunteers and in Patients with Facioscapulohumeral Muscular Dystrophy (FSHD), including an open-label patient cohort.Facioscapulohumeral muscular dystrophyLandouzy-Dejerine\u2019s disease10028302
NL-OMON48094Fulcrum Therapeutics30